Average Co-Inventor Count = 13.59
ph-index = 3
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Array Biopharma Inc. (18 from 329 patents)
2. Mirati Therapeutics, Inc. (4 from 38 patents)
3. Celgene Corporation (2 from 549 patents)
4. Genentech, Inc. (1 from 3,221 patents)
18 patents:
1. 11932633 - KRas G12C inhibitors
2. 11834453 - Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
3. 11634409 - Compounds for the treatment of BRAF-associated diseases and disorders
4. 11414404 - Compounds for the treatment of BRAF-associated diseases and disorders
5. 11267812 - KRAS G12C inhibitors
6. 11028093 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
7. 10730880 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors
8. 10669269 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
9. 10633381 - KRas G12C inhibitors
10. 10189845 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
11. 10125134 - KRas G12C inhibitors
12. 9809590 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
13. 9670208 - Serine/threonine kinase inhibitors
14. 9174981 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
15. 8987251 - Triazolopyridine compounds as PIM kinase inhibitors